Summary
No alignment to FDA-approved prescribing information could be demonstrated. All extracted claims about exclusivity/patent term were not supported by the provided label sections, and the response included an invalid/unhelpful label citation without reviewing relevant prescribing-information safety or dosing content.
Category Scores
Accurate Statements
Unsupported Statements
Kadcyla's market exclusivity is granted for 8 years.
Absent from the provided label section(s); no label text supporting an 8-year market exclusivity duration was provided.
The 8-year figure refers to market exclusivity granted under the relevant regulatory framework.
Absent from the provided label section(s); no label text describing market exclusivity, the referenced regulatory framework, or the meaning of an 8-year figure was provided.
Any additional patent term is separate from the market exclusivity period.
Absent from the provided label section(s); no label text discussing patent term, market exclusivity, or their relationship was provided.
Contradictions
Important Omissions
No FDA-label adherence review of core prescribing-information safety and use sections (e.g., BOXED WARNING, CONTRAINDICATIONS, DOSAGE AND ADMINISTRATION safety considerations, USE IN SPECIFIC POPULATIONS, and ADVERSE REACTIONS).
Importance:
Moderate
Invalid/insufficient label citation: citation value '15 REFERENCES' does not specify an actual FDA label section number or relevant content excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated response content pertains to exclusivity/patent-term assertions without evidence from prescribing information. While this does not directly drive patient dosing decisions, unsupported legal/regulatory claims indicate unreliable label alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims about 8-year market exclusivity and patent-term separation are not supported by the provided FDA label section(s), and the label citation provided is invalid/non-specific.
Suggested Improvement
Only make statements that are supported by specific, quoted FDA label sections. If prescribing information does not address market exclusivity or patent-term duration, omit those assertions and instead focus the audit on label-supported safety, dosing, and contraindication content with correct section-number citations.